19 completed, 8 active not recruiting, 8 unknown, 7 terminated. 44 Phase 2, 6 Phase 3, 3 Phase 1, 2 Not applicable.
Follow Academic and Community Cancer Research United: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Retifanlimab with Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma Bevacizumab, Biospecimen Collection, Computed Tomography - Recurrent Glioblastoma, Recurrent WHO Grade 4 Glioma | Phase 2 | Recruiting | Academic and Community Cancer Research United | 134 | 2024-10-02 | 2024-11-19 |
| Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy Biopsy, Biospecimen Collection, Computed Tomography - Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Primary Mediastinal Large B-Cell Lymphoma | Phase 2 | Recruiting | Academic and Community Cancer Research United | 120 | 2024-01-31 | 2024-09-26 |
| Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma Biopsy, Biospecimen Collection, Bone Marrow Aspiration - Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma | Phase 2 | Recruiting | Academic and Community Cancer Research United | 100 | 2024-01-04 | 2024-11-18 |
| Tucatinib Combined with Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T Study Trastuzumab, Trifluridine and Tipiracil Hydrochloride, Tucatinib - Metastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma | Phase 2 | Withdrawn | Academic and Community Cancer Research United | 2023-10-31 | 2024-09-19 | |
| Regorafenib and Durvalumab for the Treatment of High-Risk Liver Cancer Durvalumab, Regorafenib - Stage IB Hepatocellular Carcinoma AJCC v8, Stage II Hepatocellular Carcinoma AJCC v8 | Phase 2 | Active not recruiting | Academic and Community Cancer Research United | 4 | 2023-07-01 | 2026-07-20 |
| A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab Ipilimumab, Nivolumab - BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma | Phase 2 | Terminated | Academic and Community Cancer Research United | 15 | 2023-01-19 | 2026-08-04 |
| Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma Carfilzomib, Daratumumab, Dexamethasone - Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma | Phase 2 | Active not recruiting | Academic and Community Cancer Research United | 8 | 2022-12-08 | 2026-09-15 |
| Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer Atezolizumab, Cabozantinib, Lenvatinib - Locally Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma | Phase 2 | Recruiting | Academic and Community Cancer Research United | 122 | 2022-05-27 | 2026-08-04 |
| PEA for the Relief of Chemotherapy-Induced Peripheral Neuropathy Palmidrol, Placebo Administration, Quality-of-Life Assessment - Chemotherapy-Induced Peripheral Neuropathy, Hematopoietic and Lymphoid Cell Neoplasm | Phase 2 | Active not recruiting | Academic and Community Cancer Research United | 88 | 2022-05-16 | 2025-09-22 |
| Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma Acalabrutinib, Bortezomib, Cyclophosphamide - Mantle Cell Lymphoma | Phase 2 | Active not recruiting | Academic and Community Cancer Research United | 41 | 2021-08-03 | 2026-08-25 |
| Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer Paclitaxel, Quality-of-Life Assessment, Ramucirumab - Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Phase 2 | Recruiting | Academic and Community Cancer Research United | 116 | 2021-06-16 | 2024-04-01 |
| RegoNivo vs Standard of Care Chemotherapy in AGOC Regorafenib, Nivolumab, Docetaxel - Gastro-Oesophageal Cancer | Phase 3 | Completed | Australasian Gastro-Intestinal Trials Group | 462 | 2021-05-05 | 2026-06-10 |
| Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma Polatuzumab Vedotin, Rituximab, Rituximab and Hyaluronidase Human - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma | Phase 2 | Terminated | Academic and Community Cancer Research United | 3 | 2021-04-01 | 2024-09-19 |
| Gemcitabine and Cisplatin With Ivosidenib or Pemigatinib for the Treatment of Unresectable or Metastatic Cholangiocarcinoma Cisplatin, Gemcitabine, Ivosidenib - Advanced Cholangiocarcinoma, Metastatic Cholangiocarcinoma | Phase 1 | Terminated | Academic and Community Cancer Research United | 8 | 2021-01-25 | 2024-05-06 |
| Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 2019 (COVID-19) Ibrutinib, Quality-of-Life Assessment - Asymptomatic COVID-19 Infection Laboratory-Confirmed, B-Cell Neoplasm | Phase 2 | Withdrawn | Academic and Community Cancer Research United | 2020-11-23 | 2022-08-03 | |
| Binimetinib and Encorafenib for the Treatment of Pancreatic Cancer in Patients With a Somatic BRAF V600E Mutation Binimetinib, Encorafenib - Locally Advanced Pancreatic Carcinoma, Metastatic Pancreatic Carcinoma | Phase 2 | Terminated | Academic and Community Cancer Research United | 6 | 2020-11-16 | 2024-05-06 |
| T-DM1 With or Without Abemaciclib for the Treatment of HER2-Positive Metastatic Breast Cancer Abemaciclib, Trastuzumab Emtansine - Anatomic Stage IV Breast Cancer AJCC v8, HER2 Positive Breast Carcinoma | Phase 2 | Withdrawn | Academic and Community Cancer Research United | 2020-11-11 | 2022-05-26 | |
| Pemigatinib for the Treatment of Metastatic or Unresectable Colorectal Cancer Harboring FGFR Alterations Pemigatinib, Quality-of-Life Assessment - FGFR1 Gene Amplification, FGFR1 Gene Mutation | Phase 2 | Unknown | Academic and Community Cancer Research United | 14 | 2020-08-31 | 2024-02-21 |
| Daratumumab, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma Daratumumab, Dexamethasone, Pomalidomide - Recurrent Plasma Cell Myeloma | Phase 2 | Withdrawn | Academic and Community Cancer Research United | 2020-08-07 | 2022-06-15 | |
| Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging - Bile Duct Adenocarcinoma, Fanconi Anemia Complementation Group Gene Mutation | Phase 2 | Active not recruiting | Academic and Community Cancer Research United | 32 | 2020-06-24 | 2026-05-15 |
Showing 20 of 54. Sign in to see all of them.
Colorectal Neoplasms (11) · Breast Neoplasms (7) · Colonic Neoplasms (4) · Lymphoma, Mantle-Cell (4) · Neoplasm Metastasis (4) · Rectal Neoplasms (4) · Carcinoma, Hepatocellular (3) · Lymphoma, B-Cell (3) · Adenocarcinoma (2) · Adenocarcinoma, Follicular (2) · Carcinoma (2) · Hematologic Neoplasms (2) · Intracranial Thrombosis (2) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Lymphoma, B-Cell, Marginal Zone (2)
Disulfides (7) · regorafenib (7) · Immunoglobulin G (6) · Bevacizumab (5) · Trifluridine (5) · trifluridine tipiracil drug combination (5) · Magnetic Resonance Spectroscopy (4) · Nivolumab (4) · Paclitaxel (4) · Rituximab (4) · Specimen Handling (4) · Taxes (4) · CT-P10 (3) · Cetuximab (3) · Dexamethasone (3)
United States (52) · Australia (2) · Italy (2) · Japan (2) · South Korea (2) · Spain (2) · Taiwan (2) · Austria (1) · Belgium (1) · Canada (1) · France (1) · Germany (1) · New Zealand (1)
Charles Loprinzi (4) · John H Strickler (4) · Daniel H Ahn (2) · Grzegorz S Nowakowski (2) · Mehmet Akce (2) · Nick Pavlakis, Prof (2) · Alan L Ho (1) · Amber L. Isley, M.D. (1) · Aminah Jatoi (1) · Aminah Jatoi, M.D. (1) · Andrew E Hendifar (1) · Bruce D Cheson (1) · Bryan R Haugen (1) · Catherine S Diefenbach (1) · Ciara C O'Sullivan (1)
PMID 36814222, PMID 28712102, PMID 28837207, PMID 31262657, PMID 31393548, PMID 31606897, PMID 31630479, PMID 33010817, PMID 33720068, PMID 35179586, PMID 35380713, PMID 37142372, PMID 37318379, PMID 37941353, PMID 38537780, PMID 39365958, PMID 39368039, PMID 40455046, PMID 40515475, PMID 41678089, PMID 42305039
P30CA015083 (46), 2018 (1), R01CA124614 (1)